Axsome Therapeutics Inc (AXSM): Next-Year EPS Estimate 274.15%
As of 2026-09-17, Axsome Therapeutics Inc (AXSM) has a next-year EPS growth estimate of 274.15%. Featured in our EPS revision report on 2026-05-04.
On 2026-08-24, analyst consensus for AXSM's next-year EPS growth shifted from 276.98% to 274.15% — a negative change of 2.83 percentage points. The revised estimate has been sustained across 23 subsequent trading sessions. Current-year growth is projected at 27.32%.
What's Driving This
AXSM's next-year EPS growth estimate was revised down from 298.87% to 280.13% on 2026-08-11 and currently
Generated 2026-09-17 from news as of 2026-09-17
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 274.15%
- EPS growth this year
- 27.32%
- EPS next quarter (est)
- -$0.49
- Last price
- $214.28
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-09-17 | 274.15% | 27.32% | -$0.49 | $214.28 |
| 2026-09-16 | 274.15% | 27.32% | -$0.49 | $211.97 |
| 2026-09-15 | 274.15% | 27.32% | -$0.49 | $204.07 |
| 2026-09-14 | 274.15% | 27.32% | -$0.49 | $216.58 |
| 2026-09-13 | 274.15% | 27.32% | -$0.49 | $220.75 |
| 2026-09-11 | 274.15% | 27.32% | -$0.49 | $220.75 |
| 2026-09-10 | 274.15% | 27.32% | -$0.49 | $211.12 |
| 2026-09-09 | 274.15% | 27.32% | -$0.49 | $210.63 |
| 2026-09-08 | 274.15% | 27.32% | -$0.49 | $207.82 |
| 2026-09-07 | 274.15% | 27.32% | -$0.49 | $206.68 |
| 2026-09-06 | 274.15% | 27.32% | -$0.49 | $206.68 |
| 2026-09-04 | 274.15% | 27.32% | -$0.49 | $206.68 |
| 2026-09-03 | 274.15% | 27.32% | -$0.49 | $208.35 |
| 2026-09-02 | 274.15% | 27.32% | -$0.49 | $209.92 |
| 2026-09-01 | 274.15% | 27.32% | -$0.49 | $202.83 |
| 2026-08-31 | 274.15% | 27.32% | -$0.49 | $198.52 |
| 2026-08-30 | 274.15% | 27.32% | -$0.49 | $199.02 |
| 2026-08-29 | 274.15% | 27.32% | -$0.49 | $199.02 |
| 2026-08-28 | 274.15% | 27.32% | -$0.49 | $199.02 |
| 2026-08-27 | 274.15% | 27.32% | -$0.49 | $206.27 |
| 2026-08-26 | 274.15% | 27.32% | -$0.49 | $207.15 |
| 2026-08-25 | 274.15% | 27.32% | -$0.49 | $205.48 |
| 2026-08-24 | 274.15% | 27.32% | -$0.49 | $205.40 |
| 2026-08-23 | 276.98% | 27.59% | -$0.49 | $207.77 |
| 2026-08-21 | 276.98% | 27.59% | -$0.49 | $207.77 |
| 2026-08-20 | 276.98% | 27.59% | -$0.49 | $208.03 |
| 2026-08-19 | 276.98% | 27.59% | -$0.49 | $218.20 |
| 2026-08-18 | 276.98% | 27.59% | -$0.49 | $215.69 |
| 2026-08-17 | 276.98% | 27.59% | -$0.49 | $216.27 |
| 2026-08-16 | 276.98% | 27.59% | -$0.49 | $213.67 |
Reports Featuring AXSM
Recent News
- AXSM Jumps 6% As Mizuho Calls Auvelitys Alzheimers Launch A Strong StartStocktwits
- Axsome Therapeutics shares gain 2% as strong sales growth offsets Q2 missInvestorsHub
- Axsome: Q2 Earnings SnapshotAssociated Press
- Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswire
- Shopify downgraded, Five Below upgraded: Wall Street's top analyst callsThe Fly
- Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)GlobeNewswire
- TARS Stock Drops After Culper Research Accuses Tarsus Of Illegal Medicare Copay SchemeStocktwits
- TARS Stock Drops After Culper Research Accuses Tarsus Of Illegal Medicare Copay SchemeStocktwits
- Axsome Therapeutics, Inc. Q1 2026 Earnings Call SummaryMoby
- Axsome: Q1 Earnings SnapshotAssociated Press
Screen Performance
Aggregate stats across all 2046 tickers our top-EPS-revision screen has flagged over the past 169 days.
- Median return since detection
- +0.4%
- % of tickers in the green
- 51%
- Median return on winners
- +21.4%
- Large revisions captured
- 1726
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
What is Axsome Therapeutics Inc's next-year EPS growth estimate?▾
As of 2026-09-17, Axsome Therapeutics Inc (AXSM) has a next-year EPS growth estimate of 274.15%, based on analyst consensus.
When was the latest EPS estimate revision for AXSM?▾
The most recent revision occurred on 2026-08-24, when analysts adjusted the next-year EPS growth estimate from 276.98% to 274.15%.
What sector and industry does Axsome Therapeutics Inc belong to?▾
Axsome Therapeutics Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. AXSM appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Axsome Therapeutics Inc (AXSM) appears here because it was detected by our daily top-EPS-revision-performer screen.